ARAY

Accuray Inc

Add to Watchlist

Advanced Chart

1.390

+0.07(5.303%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.400

Open

1.340

VWAP

1.36

Vol

699.89K

Mkt Cap

143.19M

Low

1.320

Amount

949.66K

EV/EBITDA(TTM)

17.82

Total Shares

99.24M

239.15M

EV/OCF(TTM)

10.65

P/S(TTM)

0.30

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

124.47M

-7.31%

0.015

-50%

97.80M

-3.69%

-0.035

-12.5%

109.60M

-5.66%

-0.040

-300%

Estimates Revision

The market is revising Upward the revenue expectations for Accuray Incorporated (ARAY) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -16.27%.

Revenue Estimates for FY2025

Revise Upward

+0.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+50%

In Past 3 Month

Stock Price

Go Down

-16.27%

In Past 3 Month

3 Analyst Rating

139.57% Upside

Wall Street analysts forecast ARAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARAY is 3.33 USD with a low forecast of 1.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

139.57% Upside

Current: 1.390

Low

1.50

Averages

3.33

High

4.50

139.57% Upside

Current: 1.390

Low

1.50

Averages

3.33

High

4.50

BTIG

Buy

downgrade

$5 -> $4

2025-06-06

Reason

BTIG

Price Target

$5 -> $4

2025-06-06

downgrade

Buy

Reason

BTIG lowered the firm's price target on Accuray to $4 from $5 and keeps a Buy rating on the shares. The firm notes Accuray announced that it will exchange its convertible notes, refinance its debt, and enter into a new credit facility. The exchange is expected to be completed on June 11. This will result in Accuray having about $18M in outstanding 2026 convertible note principal, $150M in debt from the new 2030 term loan, and 15M in new shares issued, the firm notes. BTIG is pleased to see Accuray address its 2026 borrowings and believes this removes investor concerns about near-term debt maturity, while preserving a healthy balance sheet. The firm acknowledges the share dilution and potentially higher interest expense, though the paid in-kind option allows Accuray's cash outlays on interest expense to remain relatively similar going forward.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Accuray Inc (ARAY.O) is -17.38, compared to its 5-year average forward P/E of 2.31. For a more detailed relative valuation and DCF analysis to assess Accuray Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

2.31

Current PE

-17.38

Overvalued PE

190.65

Undervalued PE

-186.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

15.52

Current EV/EBITDA

11.22

Overvalued EV/EBITDA

22.51

Undervalued EV/EBITDA

8.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

0.64

Current PS

0.35

Overvalued PS

0.90

Undervalued PS

0.39